Recent evidence indicates a significant decrease in ACE2 levels in the metabolic system organs (e.g., kidney and heart) of COVID-19 patients, leading to metabolic sequelae.46,55 Therefore, restoring and upregulating ACE2 expression and activity could benefit patients facing metabolic challenges associated with COVID-19. This evidence concerns the gene ACE2 and COVID-19.